Literature DB >> 2941636

A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts.

T R Kosten, M J Kreek, J Ragunath, H D Kleber.   

Abstract

Because opioid antagonists acutely produce rises in serum beta endorphin, we studied beta endorphin levels in 21 former opiate addicts chronically taking naltrexone. The mean AM (19.5 pg/ml) beta endorphin level was higher than the AM mean for 39 normals under 40 years old (12.1 pg/ml) (t = 3.2, p less than 0.001); the mean PM level for the naltrexone treated patients was 13.6 pg/ml. Four patients had beta endorphin levels more than 2 S.D. above the mean for the normals (greater than 26.4 pg/ml), and six others had relatively elevated PM levels. Thus, 47% (10/21) had abnormal patterns of beta endorphin levels. We had previously reported abnormally high cortisol levels in these patients, and AM cortisol correlated with AM beta endorphin levels (r = 0.7, p less than 0.001). We concluded that sustained beta endorphin elevations may occur during chronic naltrexone treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941636     DOI: 10.1016/0024-3205(86)90437-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  13 in total

Review 1.  A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.

Authors:  B J Berg; H M Pettinati; J R Volpicelli
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

2.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

Review 3.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

4.  Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?

Authors:  Maria A Sullivan; Adam Bisaga; John J Mariani; Andrew Glass; Frances R Levin; Sandra D Comer; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2013-07-01       Impact factor: 4.492

5.  Naltrexone potentiates 4-aminopyridine seizures in the rat.

Authors:  A Mihály; K Bencsik; T Solymosi
Journal:  J Neural Transm Gen Sect       Date:  1990

6.  Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.

Authors:  Edward V Nunes; Adam Bisaga; Evgeny Krupitsky; Narinder Nangia; Bernard L Silverman; Sarah C Akerman; Maria A Sullivan
Journal:  Addiction       Date:  2019-08-04       Impact factor: 6.526

7.  Acute HPA axis response to naltrexone differs in female vs. male smokers.

Authors:  Daniel J O Roche; Emma Childs; Alyssa M Epstein; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2009-10-17       Impact factor: 4.905

8.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 9.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

Review 10.  Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases.

Authors:  Yan Zhou; Dmitri Proudnikov; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2009-11-12       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.